Navigation Links
Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Date:11/19/2009

MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.

The study, entitled "An Open-Label Randomized Phase 2 Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen", is being conducted in the United States and Canada and will also be conducted in Germany, subject to final regulatory approval. This clinical trial follows shortly after the completion of Aegera's first Phase 2 clinical trial in this indication, the results of which were recently reported in the Journal for Clinical Oncology (J Clin Oncol. 2009 Oct 1;27(28):4741-6).

"Strong demonstration of activity in our non-randomized Phase 2A study conducted in this indication have encouraged us to rapidly initiate a randomized Phase 2B study in AML to confirm our hypothesis that AEG35156 may indeed be significantly improving the response rates in this under-served population of AML patients. If the responses observed in this randomized study are similar to the clinical results that we have already published, we will accelerate our efforts to complete all additional trials required to apply for regulatory approval in North America, Europe and Asia" stated Dr. Jacques Jolivet, Senior Vice-President of Clinical Development of Aegera.

About AEG35156

AEG35156 is a 2nd generation antisense oligonucleotide which targets XIAP; it is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy, without harming healthy cells. Other currently enrolling studies include a Phase 1/2 monotherapy study in CLL/indolent B-cell lymphomas, which is fully funded by The Leukemia and Lymphoma Society of North America, and a Phase 1/2 randomized combination study with sorafenib in first-line hepatocellular carcinoma being conducted in Hong Kong.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing novel targeted therapies that address major unmet medical needs. In addition to AEG35156, Aegera is completing a Phase 2A study of AEG33773 in diabetic neuropathic pain and is working to progress HGS1029 through early stage clinical development with its partner Human Genome Sciences (HGSI). Additional information on these programs can be found on Aegera's website at www.aegera.com.

SOURCE AEGERA THERAPEUTICS INC.


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
2. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
3. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics welcomes two experienced executives to its board of directors
6. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
7. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
8. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
9. Fate Therapeutics Closes $30 Million Series B Financing
10. Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
11. Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... (PRWEB) , ... May 18, 2017 , ... ... activities. The Tapas Cooking Challenge is a two-hour team-building package designed for ... menu created by Chef Jodi Abel, which include items, such as Blackened Shrimp ...
(Date:5/18/2017)... , ... May 17, 2017 , ... ... in medical device compliance and commercialization, has just released version 9.0 of the ... into this latest version of Cockpit,” says David Cronin, CEO of Cognition. “We’re ...
(Date:5/18/2017)... ... May 17, 2017 , ... Many complicated neurological disorders appear ... Alzheimer’s disease, while men are at greater risk for Parkinson’s disease. Understanding some ... the aim of a research program at Worcester Polytechnic Institute (WPI) funded by ...
(Date:5/16/2017)... ... 2017 , ... Zansors has secured a patent ... EKG) acquisition and monitoring device. This Zansors’ next-generation intellectual property (IP), will allow ... skin, making them significantly easier to deploy and use. , Currently, ECG sensors ...
Breaking Biology Technology:
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
(Date:3/22/2017)... March 21, 2017 Vigilant Solutions , ... law enforcement agencies, announced today the appointment of retired ... of public safety business development. Mr. Sheridan ... experience, including a focus on the aviation transportation sector, ... recent position, Mr. Sheridan served as the Aviation Liaison ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
Breaking Biology News(10 mins):